BCL2 and melanoma: Similar to its effects on regular melanoma cells, lj-1-59 treatment causes cell cycle arrest at the G2/M phase (Fig. 6d) and apoptosis (Fig. 6e), including upregulating the expression of cleaved PARP and BAX and decreasing BCL2 expression (Fig. 6f).